Role of B cells in the pathogenesis of systemic sclerosis

Sangès, S.; Guerrier, Thomas; Launay, David; Lefèvre, Guillaume; Labalette, Myriam; Forestier, Alexandra; Sobanski, Vincent; Corli, J.; Hauspie, C.; Jendoubi, Manel; Yakoub-Agha, Ibrahim; Hatron, Pierre‐Yves; Hachulla, É.; Dubucquoi, Sylvain

doi:10.1016/j.revmed.2016.02.016

Cited by 40 publications

(34 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systemic sclerosis (SSc) is a complex disease resulting from impaired biological cell function, affecting endothelial cells,fibroblasts,lymphocytes,monocytes,andbonemarrow cells (1)(2)(3)(4).Vasculopathyandtissuefibrosisoccurasaresult oftheseimpairmentsandareconsideredtobethemainclinicalfeaturesofpatientswithSSc.Thesepatientshavedysregulation of genetic and epigenetic function (5-7), innate immunity(8),andresponsetoinfections,resultinginaberrant immuneactivationandacceleratedtissuedamageleadingto tissuefibrosis,vasculopathy,andautoimmunity.Inthepast2 decades,manycytokines (9)(10)(11)(12)(13)(14)(15)(16)(17)(18),chemokines (19)(20)(21),growth factors (22)(23)(24)(25)(26),andtranscriptionfactors (27,28)havebeen studied for their potential involvement in the pathogenesis of SSc. For example, in vitro and in vivo experiments using sclerodermamurinemodelshaverevealedthattransforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor may play crucial roles in collagen production by tissue fibroblasts in SSc (22)(23)(24)(25)(26).Inadditiontothesegrowthfactors,cytokines-including interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-8, IL-13, IL-33, and IL-35 -were found to be potent regulators of tissue…”

Section: Introductionmentioning

confidence: 99%

Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

Kawaguchi

2017

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Systemicsclerosis(SSc)isaconnectivetissuediseaseofunknownetiology,manifestinginpatientsastissuefibrosis,endothelialdysfunction,andinflammation.Thediseaseischaracterizedbyautoantibodies,ahallmarkof autoimmunity.Variouscytokinesandgrowthfactorsareelevatedinthesystemiccirculationandfibroticlesions ofpatientswithSSc.Inparticular,severalstudiesoverthepast2decadeshaveshownthatinterleukin-6(IL-6) appearstobeinvolvedinthepathogenesisofSSc.BasedontheassociationbetweenaberrantIL-6production andtissuefibrosisinpatientswithSSc,theanti-IL-6receptorantibody,tocilizumab,isbeinginvestigatedinclinical trials.ThisarticlereviewsthebiologicalfeaturesofIL-6andtheIL-6receptor;theroleofIL-6inthepathogenesis ofSSc;andthepotentialforIL-6inhibitiontobeusedinthetreatmentofpatientswithSSc.

show abstract

Section: Introductionmentioning

confidence: 99%

Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

Kawaguchi

2017

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

show abstract

“…Systemic sclerosis (SSc) is a chronic connective tissue disease including various degrees of vascular involvement, tissue fibrosis and inflammation/auto-immunity [1,2]. SSc affects around 9 women for 1 man [3].…”

Section: Introductionmentioning

confidence: 99%

Special considerations in pregnant systemic sclerosis patients

Sobanski

Launay

Depret

et al. 2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Evaluating the fertility and pregnancy outcomes in systemic sclerosis (SSc) women is challenging. Studies are still limited or subject to potential methodological biases. Areas covered: This work is a comprehensive review of the literature. We discuss the potential impact of SSc on women's pregnancy outcomes and the effects of pregnancy on SSc. We summarize the physiological changes during pregnancy and describe our experience. Expert commentary: Although the miscarriage rate does not appear increased in SSc, women are exposed to a higher risk of premature birth and intrauterine growth restriction compared with the general population. Early diffuse cutaneous SSc and use of corticosteroids are risk factors, whereas folic acid use prevents against premature birth. All SSc women wishing to conceive should be counselled during a preconception visit. Physiological changes arising during pregnancy may be the source of clinical problems in SSc women with organs with limited capacities.

show abstract

“…В особых случаях, когда в клинической картине преобладает тяжелое поражение сердца, а стандартная терапия не оказывает достаточного эффекта, возникает необходимость рассмотреть альтернативные варианты лечения. Хотя механизмы, лежащие в основе развития ССД, остаются не до конца изученными, данные целого ряда исследований подтверждают участие В-лимфоцитов в патогенезе воспалительных процессов и фиброзообразования при ССД [12]. Ключевая роль В-клеток делает перспективным применение анти-В-клеточной терапии при ССД [12].…”

unclassified

Effect of rituximab on heart involvement in systemic sclerosis

Garzanova¹,

Ананьева²,

Koneva³

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

As of now, there has been a great body of data on the use of rituximab (RTM) in systemic sclerosis (SS), mainly on its positive effect on skin fibrosis and lung injury. However, information is still scarce about the effect of RTM on other organs and systems, namely the heart affected by SS.Objective: to assess the time course of changes in the signs of heart involvement in SS patients one year after initiation of RTM therapy.Subjects and methods. The paper gives data on changes in cardiac disorders in 71 patients with SS one year after the prescription of RTM.Results and discussion. The rate of cardiac rhythm and conduction disorders and diastolic dysfunction was unchanged. At the same time, a significant increase in left ventricular ejection fraction (EF) and a reduction in the severity of dyspnea was achieved, which correlated with improved lung function (a significant rise in forced vital capacity). The results of treatment in three patients with predominant heart involvement associated with SS (coronary heart disease and hypertension were ruled out) were considered in detail. These patients displayed pronounced positive changes as increased EF, less severe cardiac arrhythmias, reduced chronic heart failure, better quality of life, as well as the synchronicity of lower disease activity, less skin induction, improved lung function, and stabilized pulmonary artery systolic pressure.Conclusion. RTM in combination with traditional therapy can be considered as a potentially effective drug for the treatment of heart involvement in SS.

show abstract

Role of B cells in the pathogenesis of systemic sclerosis

Cited by 40 publications

References 110 publications

Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis

Special considerations in pregnant systemic sclerosis patients

Effect of rituximab on heart involvement in systemic sclerosis

Contact Info

Product

Resources

About